Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

13.81
+0.05000.36%
Post-market: 13.830.0200+0.14%19:05 EDT
Volume:2.84M
Turnover:39.23M
Market Cap:10.71B
PE:-8.67
High:14.08
Open:13.46
Low:13.36
Close:13.76
52wk High:30.98
52wk Low:12.55
Shares:775.37M
Float Shares:130.76M
Volume Ratio:0.93
T/O Rate:2.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5932
EPS(LYR):-1.4439
ROE:-270.95%
ROA:-148.15%
PB:19.61
PE(LYR):-9.56

Loading ...

Summit drops as concerns over older patients cloud cancer trial data

Reuters
·
Jun 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (SMMT), Oculis Holding (OCS) and Cogent Biosciences (COGT)

TIPRANKS
·
Jun 01

Summit Therapeutics Shares Rise 4.1% Premarket After Co's Lung Cancer Drug With China-Based Partner Shows 15% Higher Survival Rate Than Rival's

THOMSON REUTERS
·
Jun 01

Summit Therapeutics Says Ivonescimab Improves Survival Over Tislelizumab in Phase III Lung Cancer Trial

MT Newswires Live
·
Jun 01

Stock Track | Summit Therapeutics Soars 9.06% in Pre-market on Positive Lung Cancer Drug Trial Results

Stock Track
·
Jun 01

Stock Track | Summit Therapeutics Soars 11.46% on Positive Ivonescimab Lung Cancer Trial Results

Stock Track
·
Jun 01

Summit Therapeutics posts HARMONi-6 ASCO 2026 plenary slides on ivonescimab in squamous NSCLC

Reuters
·
Jun 01

Summit Therapeutics announces OS results from Phase 3 HARMONi-6 trial

TIPRANKS
·
May 31

Summit Therapeutics presents new results from AK112-206 trial

TIPRANKS
·
May 31

CORRECTED-Akeso lung cancer drug helps patients live 15% longer than immunotherapy in China trial (May 31)

Reuters
·
May 31

BioNTech's Cancer Pipeline Seen Strengthening Ahead of Key Trial Results, UBS Says

MT Newswires Live
·
May 28

Assessing Summit Therapeutics (SMMT) Valuation As Ivonescimab Development Draws Fresh Investor Attention

Simply Wall St.
·
May 24

Summit Therapeutics Downgraded by H.C. Wainwright Amid Merck ADC Data Concerns

Deep News
·
May 23

This Summit Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Friday

Benzinga
·
May 23

S&P 500 Futures Climb In Premarket Trading; WR Berkley, Summit Therapeutics Lag

Dow Jones
·
May 22

Summit Therapeutics Plc : H.c. Wainwright Cuts to Neutral From Buy

THOMSON REUTERS
·
May 22

U.S. RESEARCH ROUNDUP-Jazz Pharmaceuticals, Target, Workday

Reuters
·
May 22

Used EV sales soar as drivers look to curb fuel costs

cityam
·
May 12

Summit Therapeutics (SMMT) Is Down 20.1% After Q1 2026 Net Loss Widens Sharply

Simply Wall St.
·
May 11

Stock Track | Summit Therapeutics Plummets 5.01% Intraday as H.C. Wainwright Cuts Target Price Amid Clinical Data Concerns

Stock Track
·
May 08